3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
4
Classical hematology
1
Conditions
Venous Thromboembolism
8
Thrombocythemia, Essential
2
Primary Myelofibrosis
2
Polycythemia Vera
2
Neoplasms
2
Thrombosis
1
Thrombocytopenia
1
Testicular Neoplasms
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Myocardial Infarction
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Hemorrhage
1
Hematoma
1
Hematologic Diseases
1
Glioblastoma
1
Bone Neoplasms
1
Acute Coronary Syndrome
1
Interventions
fludarabine phosphate
34
Cyclophosphamide
34
Peripheral Blood Stem Cell Transplantation
23
Busulfan
22
Mycophenolic Acid
21
Cyclosporine
20
Whole-Body Irradiation
19
Tacrolimus
18
Antilymphocyte Serum
18
Melphalan
16
Filgrastim
16
Radiotherapy
15
Methotrexate
14
fludarabine
12
Cord Blood Stem Cell Transplantation
12
Methylprednisolone
10
Cytarabine
10
Etoposide
8
sargramostim
6
Granulocyte Colony-Stimulating Factor
5
Cyclosporins
5
Alemtuzumab
4
thymoglobulin
3
merphos
3
Tretinoin
3
Thiotepa
3
Thalidomide
3
Sirolimus
3
Rituximab
3
Leucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Aspirin
×
Classical hematology
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled